{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-001569","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2025-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.578308+00:00","generated_at":"2026-05-27T19:56:10.385207+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NRx regains Nasdaq compliance; appoints Mike Taylor director amid $25M HOPE investment term sheet","bullets":["Received Nasdaq notice on Jan 17 that it regained MVLS compliance; requirement met on Jan 16 after 10 consecutive trading days above $35M.","Appointed Mike Taylor as Class I director, filling vacancy from Janet Rehnquist resignation, effective Jan 15.","Taylor designated by JGS Holdings per term sheet for $25M in HOPE Series A Preferred convertible into 1/3 of HOPE equity and $2M for 730k NRXP shares.","Nasdaq closed the matter, removing delisting risk from the Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-001569","json":"https://secwatch.observer/filing/0001437749-25-001569.json","markdown":"https://secwatch.observer/filing/0001437749-25-001569.md","text":"https://secwatch.observer/filing/0001437749-25-001569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925001569/0001437749-25-001569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925001569/nrxp20250122_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T19:56:10.385207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39bf373958","claim":"Mike Taylor was appointed as Director at NRX Pharmaceuticals, Inc..","evidence_excerpt":"On January 15, 2025, NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Mike Taylor as a Class I member of the Board of Directors of the Company (“ Board ”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925001569/0001437749-25-001569-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"51d47402b1","claim":"Janet Rehnquist resigned as Director at NRX Pharmaceuticals, Inc..","evidence_excerpt":"Mr. Taylor was appointed to fill the seat vacated as a result of the resignation from the Board of Janet Rehnquist on January 7, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925001569/0001437749-25-001569-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}